Skip to main content

Table 3 Dietary composition and exercise volume during intervention period and post- ingestion period

From: Oral intake of a combination of glucosyl hesperidin and caffeine elicits an anti-obesity effect in healthy, moderately obese subjects: a randomized double-blind placebo-controlled trial

 

Intervention period

Post-ingestion period

Item

Group

n

Week-0

Week-4

Week-8

Week-12

Week-16

Energy (kcal/3d)

Placebo

14

6075 ± 1336

5925 ± 934

5648 ± 1108**

5623 ± 872

5488 ± 924*

GH

15

5599 ± 1387

5748 ± 1500

5383 ± 1250

5322 ± 1259

5328 ± 1013

GH + Caf 25

15

5606 ± 1270

5512 ± 1031

5252 ± 1340

4981 ± 1291

5155 ± 1395

GH + Caf 50

15

5240 ± 1463

5774 ± 1666

5425 ± 1538

5302 ± 1723

5272 ± 1635

GH + Caf 75

15

5727 ± 929

5268 ± 1369

5546 ± 1302

5119 ± 1538

5401 ± 1618

Exercise volume (step/3d)

Placebo

14

21661 ± 12162

22372 ± 9366

27058 ± 11735

25258 ± 10247

23994 ± 10039

GH

15

17118 ± 7809

22161 ± 15033

19231 ± 8677

22738 ± 11305*

20298 ± 8622

GH + Caf 25

15

19929 ± 8679

22946 ± 14412

22350 ± 16172

19656 ± 16855

22996 ± 14817

GH + Caf 50

15

23513 ± 13156

21881 ± 12157

22491 ± 9911

23005 ± 12524

24650 ± 12288

GH + Caf 75

15

18843 ± 7455

19828 ± 6532

24016 ± 8703

24036 ± 9488

23972 ± 8216

  1. GH glucosyl hesperidin 500 mg, Caf 25, 50, 75 caffeine 25 mg, 50 mg, 75 mg
  2. Data are the mean ± SD recorded 3 days before each check-up
  3. *p < 0.05, **p < 0.01 vs. baseline (week-0), (paired t-test)